EULAR OP0041 (2024) COMPARISON OF b/tsDMARDs ABOUT NON-INFLAMMATORY PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS–ANSWER LONGITUDINAL COHORT STUDY. 25% RA have significant non-inflammatory pain https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

• EULAR Abstract Archive

EULAR OP0092 (2024) INFECTIONS IN PATIENTS WITH RA TREATED WITH JAKi COMPARED TO bDMARDs: AN INTERNATIONAL COLLABORATION OF REGISTERS (THE “JAK-POT” STUDY) TNF,OMA,JAK 7-10/100 pt.yr no signif diff except for zoster >30,000pts https://t.co/XWnzuVMlbn @RheumNow #EULAR2024

• EULAR Abstract Archive

RISK OF NON-MELANOMA SKIN CANCER WITH TNFi AND OTHER bDMARDs IN PATIENTS WITH PSORIATIC ARTHRITIS: A SWEDISH AND DANISH COHORT STUDY- despite having minimal sun 25% increase NMSC TNFis vs other bDMARDs - skin checks ! @RheumNow #EULAR2024

lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @RheumNow #EULAR2024

IL-6 Immunotherapy for knee OA PPV-06 FTIH Phase 1 Is it safe? looks it, no serious AES, 6mo follow up Is it immunogenic? apparently so, IL-6 Ab & neutralizing Ab Does it work? will have to wait for Phase 2 Somehow bold knowing TCZ did not work in hand OA AbstLBA0011 #EULAR2024… https://t.co/pO0Dx3jl8E https://t.co/p1zYUtgFoM

• https://twitter.com/i/web/status/1801894324684157080
• https://twitter.com/AurelieRheumo/status/1801894324684157080/photo/1
• https://twitter.com/AurelieRheumo/status/1801894324684157080/photo/1

Nipocalimab (anti-FcRn - i.e. PLEX-in-a-bottle) with a positive phase 2 in Sjogren’s. This study is in high systemic dx pts (with nice response matching biological plausibility) - but salivary flow improved too ESSPRI didn’t quite make it, but close #EULAR2024 LBA0010 @RheumNow https://t.co/PslFKJBOOr

• https://twitter.com/drdavidliew/status/1801886350591099208/photo/1
• https://twitter.com/drdavidliew/status/1801886350591099208/photo/1
• https://twitter.com/drdavidliew/status/1801886350591099208/photo/1
• https://twitter.com/drdavidliew/status/1801886350591099208/photo/1

EFFICACY & SAFETY OF IZOKIBEP, A NOVEL IL-17A INHIBITOR, IN PATIENTS WITH ACTIVE PSA: WEEK 16 RESULTS FROM A RANDOMIZED, DB,PBO CONTROLLED, MULTICENTER 2b/3 STUDY ACR responses 60:40:20 42% MDA PASI 100 47% ho hum same as others-how many IL17s do we need ? @RheumNow #EULAR2024

Points to consider in pregnancy in #rheumatic diseases 3 points ✅TNFi all OK 👍 ? Only if you can’t control disease use other #bDMARDs Baby #vaccinations if exposed to #biologics while present #rotovirus ok other live vaccines >6 mos #EULAR2024 @eular_org @RheumNow https://t.co/MyJdA7p7zh

• https://twitter.com/Janetbirdope/status/1801881956491104300/photo/1
• https://twitter.com/Janetbirdope/status/1801881956491104300/photo/1

#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @RheumNow https://t.co/lk42I7Mn8B

• https://twitter.com/Yuz6Yusof/status/1801876904506478640/photo/1
• https://twitter.com/Yuz6Yusof/status/1801876904506478640/photo/1

EULAR guidelines for screening for TB in rheumatic disease patients #EULAR2024 https://t.co/jaixl8lGkY

• https://twitter.com/BolekBerqui/status/1801595607275991188/photo/1

POS0277: proof of concept: Prophlx with canakinumab x 1 dose rather than steroids/colch/NSAIDS when starting pegloticase with MTX in pts with active, refractory gout: 11 pts: #gout flares 0 (compared 54% in MIRROR-C), infusion rxn 0, no safety signal @rheumnow https://t.co/4qFnQTOuq0

• https://twitter.com/KDAO2011/status/1801539126719594706/photo/1

Maintenance of remission in GPA/MPA. RTX for 48 months sounds good to me. #EULAR2024 https://t.co/5YGwOHhCuX

• https://twitter.com/NoufAhmedAlham2/status/1801589237952782644/photo/1

Cohort from Netherlands 400+ PsA pts IR first bioDMARD 300+ switched TNFi->IL-17i, 99 cycled TNFi->TNFi 3year retention rates 12 mo 75% cyclers 80% swappers 24mo 60% cyclers 56% swappers No difference in treatment failure or DAS28 CRP #EULAR2024 @RheumNow POS0278 https://t.co/J8ONjVAFqG

• https://twitter.com/AurelieRheumo/status/1801520487605911565/photo/1

#EULAR2024 OP0193 Watch out, blinatumomab will BiTE! Bi-specific T-cell engagers (BiTEs), kill Bcells by engaging Tcells. In 6 refractory #RA patients (failed 3 x ts/bDMARDs), deep blood & tissue depletion were met, good response. Brief raised temp but no cytokine storm @RheumNow https://t.co/OmxSbTXfZq

• https://twitter.com/Yuz6Yusof/status/1801644379829879176/photo/1
• https://twitter.com/Yuz6Yusof/status/1801644379829879176/photo/1